Evidence map›Paper›PMID 26632464›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2015

[Study of NK cells dysfunction in multiple myeloma patients].

Wenmin Han, Xiuwen Zhang, Zhuxia Jia, Jinyuan He, Hongying Chao, Jianhe Yang, Rong Xiao, Xuzhang Lu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wenmin HanDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Xiuwen ZhangDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Zhuxia JiaDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Jinyuan HeDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Hongying ChaoDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Jianhe YangDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Rong XiaoDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Xuzhang LuDepartment of Hematology, Changzhou No.2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China.
Changzhou No.2 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the mechanism of NK cell dysfunction in patients with multiple myeloma (MM).

methodsThe expression of inhibitory receptors (CD158a and CD158b) and activating receptors NKG2D and NCRs (NKp30, NKp44 and NKp46) on CD3-CD56+NK cell of 13 MM patients and 30 healthy controls were analyzed by flow cytometry. The concentration of soluble NKG2D ligands (MICA, MICB, ULBP1, ULBP2 and ULBP3) in serum was detected by enzyme- linked immunosorbent assay (ELISA), and the cytotoxicity of NK cell against MM cell line by flow cytometry.

resultsThere are no significant differences of percentage and absolute number of NK cells, and the expression level of CD158a and CD158b between MM patients and healthy individuals (P>0.05). No NKp44 expression was detected on fresh isolated NK cells from both groups. There is no difference in inhibitor receptors expression between MM patients and healthy individuals but the expression of NKG2D, NKp30 and NKp46 on NK cells were higher in MM patients as compared with that in healthy individuals. The concentration of soluble NKG2D ligands in serum was higher in MM patients as compared with that in healthy individuals (P<0.05). Cultured healthy individual's NK cells with MM patient's serum could significantly decrease its cytotoxicity against MM cell line U266 cells [(38.5 ± 6.5) % vs (25.4 ± 5.9)%, P=0.044］.

conclusionThe higher level of soluble NKG2D ligands in serum may be the mechanism of NK cell dysfunction in MM patient.

Indexed as

Cells, CulturedFlow CytometryHumansKiller Cells, NaturalMultiple MyelomaNatural Cytotoxicity Triggering Receptor 1Natural Cytotoxicity Triggering Receptor 2Natural Cytotoxicity Triggering Receptor 3NK Cell Lectin-Like Receptor Subfamily KReceptors, KIR2DL1Receptors, KIR2DL3KLRK1 protein, humanNatural Cytotoxicity Triggering Receptor 1Natural Cytotoxicity Triggering Receptor 2Natural Cytotoxicity Triggering Receptor 3NCR1 protein, humanNCR2 protein, humanNCR3 protein, humanNK Cell Lectin-Like Receptor Subfamily KReceptors, KIR2DL1Receptors, KIR2DL3

Identifiers

PMID26632464
PMCPMC7342427
OpenAlexW2337874594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.